Yamin Shu

机构：Peking University, Peking University International Hospital, Tongji Hospital, Huazhong University of Science and Technology · ORCID：0000-0002-1532-8135

发表论文 49 篇 · 总被引 1409 次 · h-index 20

代表论文

• Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system (2023 · Frontiers in Immunology · 被引 44)
• Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system (2023 · CNS Neuroscience & Therapeutics · 被引 29)
• A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data (2023 · BMC Cancer · 被引 25)
• Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment (2023 · Drug Safety · 被引 20)
• Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study (2025 · BMJ Open · 被引 19)
• Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (2023 · International Immunopharmacology · 被引 15)